vs
null（GPRO）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是null的1.1倍（$219.9M vs $201.7M），Orthofix Medical Inc.同比增速更快（2.0% vs 0.4%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $15.0M），过去两年null的营收复合增速更高（13.9% vs 8.0%）
GoPro, Inc.是2002年由尼克·伍德曼创立的美国科技企业，最初注册名为伍德曼实验室，总部坐落于加利福尼亚州圣马特奥。该公司主营运动相机生产制造，同时还自主开发配套移动端应用与视频编辑软件。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
GPRO vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.1倍
$201.7M
营收增速更快
OFIX
高出1.6%
0.4%
自由现金流更多
OFIX
多$1.9M
$15.0M
两年增速更快
GPRO
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $201.7M | $219.9M |
| 净利润 | — | $-2.2M |
| 毛利率 | 31.8% | 71.1% |
| 营业利润率 | -4.1% | 0.2% |
| 净利率 | — | -1.0% |
| 营收同比 | 0.4% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | $-0.06 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GPROOFIX
| Q4 25 | $201.7M | $219.9M | ||
| Q3 25 | $162.9M | $205.6M | ||
| Q2 25 | $152.6M | $203.1M | ||
| Q1 25 | $134.3M | $193.6M | ||
| Q4 24 | $200.9M | $215.7M | ||
| Q3 24 | $258.9M | $196.6M | ||
| Q2 24 | $186.2M | $198.6M | ||
| Q1 24 | $155.5M | $188.6M |
净利润GPROOFIX
| Q4 25 | — | $-2.2M | ||
| Q3 25 | $-21.3M | $-22.8M | ||
| Q2 25 | $-16.4M | $-14.1M | ||
| Q1 25 | $-46.7M | $-53.1M | ||
| Q4 24 | — | $-29.1M | ||
| Q3 24 | $-8.2M | $-27.4M | ||
| Q2 24 | $-47.8M | $-33.4M | ||
| Q1 24 | $-339.1M | $-36.0M |
毛利率GPROOFIX
| Q4 25 | 31.8% | 71.1% | ||
| Q3 25 | 35.1% | 72.2% | ||
| Q2 25 | 35.8% | 68.7% | ||
| Q1 25 | 32.1% | 62.8% | ||
| Q4 24 | 34.7% | 69.0% | ||
| Q3 24 | 35.5% | 68.7% | ||
| Q2 24 | 30.5% | 67.8% | ||
| Q1 24 | 34.1% | 67.5% |
营业利润率GPROOFIX
| Q4 25 | -4.1% | 0.2% | ||
| Q3 25 | -9.8% | -8.3% | ||
| Q2 25 | -9.2% | -7.9% | ||
| Q1 25 | -33.7% | -25.2% | ||
| Q4 24 | -19.5% | -5.3% | ||
| Q3 24 | -3.1% | -9.6% | ||
| Q2 24 | -25.0% | -12.5% | ||
| Q1 24 | -26.6% | -15.6% |
净利率GPROOFIX
| Q4 25 | — | -1.0% | ||
| Q3 25 | -13.0% | -11.1% | ||
| Q2 25 | -10.8% | -6.9% | ||
| Q1 25 | -34.8% | -27.4% | ||
| Q4 24 | — | -13.5% | ||
| Q3 24 | -3.2% | -13.9% | ||
| Q2 24 | -25.7% | -16.8% | ||
| Q1 24 | -218.1% | -19.1% |
每股收益（稀释后）GPROOFIX
| Q4 25 | $-0.06 | $-0.05 | ||
| Q3 25 | $-0.13 | $-0.57 | ||
| Q2 25 | $-0.10 | $-0.36 | ||
| Q1 25 | $-0.30 | $-1.35 | ||
| Q4 24 | $-0.22 | $-0.76 | ||
| Q3 24 | $-0.05 | $-0.71 | ||
| Q2 24 | $-0.31 | $-0.88 | ||
| Q1 24 | $-2.24 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.7M | $82.0M |
| 总债务越低越好 | $44.3M | — |
| 股东权益账面价值 | $76.5M | $450.0M |
| 总资产 | $428.0M | $850.6M |
| 负债/权益比越低杠杆越低 | 0.58× | — |
8季度趋势，按日历期对齐
现金及短期投资GPROOFIX
| Q4 25 | $49.7M | $82.0M | ||
| Q3 25 | $152.8M | $62.9M | ||
| Q2 25 | $58.6M | $65.6M | ||
| Q1 25 | $69.6M | $58.0M | ||
| Q4 24 | $102.8M | $83.2M | ||
| Q3 24 | $130.2M | $30.1M | ||
| Q2 24 | $133.0M | $26.4M | ||
| Q1 24 | $133.7M | $27.0M |
总债务GPROOFIX
| Q4 25 | $44.3M | — | ||
| Q3 25 | $43.9M | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | $0 | $157.0M | ||
| Q3 24 | $93.1M | $118.5M | ||
| Q2 24 | $92.9M | $118.0M | ||
| Q1 24 | $92.7M | $118.2M |
股东权益GPROOFIX
| Q4 25 | $76.5M | $450.0M | ||
| Q3 25 | $80.5M | $442.5M | ||
| Q2 25 | $97.9M | $458.3M | ||
| Q1 25 | $110.0M | $458.3M | ||
| Q4 24 | $151.7M | $503.1M | ||
| Q3 24 | $183.9M | $525.9M | ||
| Q2 24 | $184.7M | $546.0M | ||
| Q1 24 | $224.9M | $570.3M |
总资产GPROOFIX
| Q4 25 | $428.0M | $850.6M | ||
| Q3 25 | $538.6M | $832.6M | ||
| Q2 25 | $439.0M | $837.2M | ||
| Q1 25 | $462.5M | $823.1M | ||
| Q4 24 | $543.7M | $893.3M | ||
| Q3 24 | $661.6M | $867.9M | ||
| Q2 24 | $556.8M | $882.0M | ||
| Q1 24 | $575.8M | $906.0M |
负债/权益比GPROOFIX
| Q4 25 | 0.58× | — | ||
| Q3 25 | 0.55× | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | 0.00× | 0.31× | ||
| Q3 24 | 0.51× | 0.23× | ||
| Q2 24 | 0.50× | 0.22× | ||
| Q1 24 | 0.41× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $15.6M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $15.0M | $16.8M |
| 自由现金流率自由现金流/营收 | 7.4% | 7.6% |
| 资本支出强度资本支出/营收 | 0.3% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-24.0M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流GPROOFIX
| Q4 25 | $15.6M | $27.7M | ||
| Q3 25 | $12.2M | $12.4M | ||
| Q2 25 | $8.8M | $11.6M | ||
| Q1 25 | $-57.2M | $-18.4M | ||
| Q4 24 | $-25.1M | $23.7M | ||
| Q3 24 | $-2.2M | $11.7M | ||
| Q2 24 | $605.0K | $9.0M | ||
| Q1 24 | $-98.4M | $-18.6M |
自由现金流GPROOFIX
| Q4 25 | $15.0M | $16.8M | ||
| Q3 25 | $11.2M | $2.5M | ||
| Q2 25 | $8.3M | $4.5M | ||
| Q1 25 | $-58.5M | $-25.1M | ||
| Q4 24 | $-25.5M | $15.2M | ||
| Q3 24 | $-4.2M | $6.3M | ||
| Q2 24 | $-111.0K | $-360.0K | ||
| Q1 24 | $-99.4M | $-29.1M |
自由现金流率GPROOFIX
| Q4 25 | 7.4% | 7.6% | ||
| Q3 25 | 6.9% | 1.2% | ||
| Q2 25 | 5.4% | 2.2% | ||
| Q1 25 | -43.5% | -13.0% | ||
| Q4 24 | -12.7% | 7.0% | ||
| Q3 24 | -1.6% | 3.2% | ||
| Q2 24 | -0.1% | -0.2% | ||
| Q1 24 | -63.9% | -15.4% |
资本支出强度GPROOFIX
| Q4 25 | 0.3% | 4.9% | ||
| Q3 25 | 0.6% | 4.8% | ||
| Q2 25 | 0.3% | 3.5% | ||
| Q1 25 | 1.0% | 3.5% | ||
| Q4 24 | 0.2% | 4.0% | ||
| Q3 24 | 0.8% | 2.7% | ||
| Q2 24 | 0.4% | 4.7% | ||
| Q1 24 | 0.6% | 5.6% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GPRO
| Subscription And Services | $106.3M | 53% |
| Other | $95.4M | 47% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
